The realistic timeline: pivotal trial results by mid-2026, NDA submission by late 2026, FDA decision by mid to late 2027, and pharmacy availability by late 2027 or early 2028
A reciprocal interaction between food-motivated behavior and diet-induced obesity
Body composition adaptation sometimes pauses before resuming
After trials were identified as meeting the systemic review inclusion criteria, they underwent another round of screening that was specific to each ITC
A large real-world study published in 2026 in the journal Inflammatory Bowel Diseases found that GLP-1 use in people with UC and Crohns disease was linked to lower rates of steroid use, hospitalization, and intestinal surgery
Figure 8: Photograph of Professor Benjamin Moore as a young man, credit: Wellcome Library